ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "juvenile idiopathic arthritis (JIA) and registry"

  • Abstract Number: 366 • 2017 ACR/ARHP Annual Meeting

    Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom

    Lianne Kearsley-Fleet1, Diederik De Cock1, Eileen Baildam2, Michael W. Beresford3, Helen E. Foster4, Taunton R. Southwood5, Wendy Thomson6,7 and Kimme L. Hyrich1,6, 1Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 3Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, 4Institute of Cellular Medicine and Paediatric Rheumatology, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, 5Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, 6National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 7Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom

    Background/Purpose: Juvenile idiopathic arthritis (JIA) comprises 7 ILAR categories, but systemic-onset JIA (sJIA) appears to be distinct in genetic background and pathogenesis from the other…
  • Abstract Number: 2272 • 2017 ACR/ARHP Annual Meeting

    Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry

    Daniel J Lovell1, N Ruperto2, N Tzaribachev3, A Zeft4, Rolando Cimaz5, V Stanevica6, Gerd Horneff7, John F. Bohnsack8, Thomas A. Griffin9, R Carrasco10, Maria Trachana11, Jason A Dare12, I Foeldvari13, Richard K Vehe14, TA Simon15, Hermine I. Brunner16 and Alberto Martini2, 1Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, 2Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, 3University Medical Center Schleswig-Holstein, Bad Bramstedt, Germany, 4Cleveland Clinic, Cleveland, OH, 5Azienda Ospedaliero-Universitaria Meyer, Florence, Italy, 6Riga Stradins University, Riga, Latvia, 7Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, 8University of Utah School of Medicine, Salt Lake City, UT, 9Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC, 10Specially For Children, Austin, TX, 11Hippokration General Hospital, Thessaloniki, Greece, 12University of Arkansas for Medical Sciences, Little Rock, AR, 13Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, 14University of Minnesota, Minneapolis, MN, 15Bristol-Myers Squibb, Princeton, NJ, 16Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Abatacept is an FDA- and EMA-approved biologic that is widely used in children with juvenile idiopathic arthritis (JIA). The purpose of this long-term ongoing…
  • Abstract Number: 2421 • 2015 ACR/ARHP Annual Meeting

    Experience with Adalimumab for Treatment of 568 Juvenile Idiopathic Arthritis Patients in the German JIA Biologics Register

    Gerd Horneff1, Gerd Ganser2, Ivan Foeldvari3, Johannes Peter Haas4, Toni Hospach5, Ralf Trauzeddel6, Frank Weller-Heinemann7, J B. Kuemmerle-Deschner8, Angelika Thon9 and BIKER study group, 1Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 2Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, 3Rheumatology, Scleroderma, Hamburg, Germany, 4German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, 5Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, 6HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, 7PRINTO, Genoa, Italy, 8Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, 9Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany

    Background/Purpose: Adalimumab (ADA) has become a valuable option for treatment of juvenile idiopathic arthritis (JIA), which significantly improves the outcome of patients. The aim of…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.